Australia's CSL names GSK executive Waterhouse as next CEO

Australian biotechnology company CSL on Wednesday named GSK executive Deborah Waterhouse as ​its next chief executive and managing director, effective February, seeking to turn a budding share-price recovery into sustained earnings growth.

Kennedy says Trump administration aims for regulated market for peptides

U.S. Health Secretary Robert F. Kennedy Jr. said the Trump ​administration aims to expand access to peptides by creating a regulated marketplace for the drugs.

25 must-visit destinations for 2027, according to National Geographic

National Geographic's 2027 list of 25 must-visit destinations for the year ahead is one of its most timely and experience-driven recommendations yet.

US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment

The US FDA said on Tuesday it had approved British drugmaker GSK's hepatitis B ​drug Hibsago, allowing patients with the liver infection a way to keep the virus under control after stopping treatment.

Nigeria reports first Ebola case in a decade in woman who arrived from Uganda

Nigeria reported its first Ebola case in about a decade ​on Tuesday after a foreign woman living in the capital tested positive for the viral infection after arriving from Uganda.

Early flu season, current strain may signal risk for younger people; doctors urge shots

Doctors are urging Americans aged 6 months and older to get vaccinated against the flu after an unusual early rise in cases on the West Coast that virologists are still working to ​understand.

A unicorn villain, Dolly Parton and skeletal headgear lead Google's 2026 costume searches

A look at what is trending on Google Halloween searches reveals the scary lowdown for 2026.

AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial

Amgen and AstraZeneca said on Tuesday their asthma drug helped reduce ​swallowing difficulties and achieved disease remission in 69% of patients with a type of chronic inflammatory disorder of the ‌esophagus.

Drug developer Lycia Therapeutics targets $938 million valuation in US IPO

Drug developer Lycia Therapeutics said on Tuesday it was targeting a ​valuation of up to $937.7 million in its US initial public offering, as biotech companies flock to the IPO ‌market.

AstraZeneca partners with Oracle for AI-driven clinical trials

AstraZeneca said on Tuesday that it is ​working with Oracle to use AI and real-world data to identify eligible patients for ‌clinical trials and monitor safety signals, among other measures, as ⁠the drugmaker looks ​to improve clinical research.